Clinical Trial: Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL-2)

U.S., Sept. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07800572) titled 'Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL-2)' on Aug. 29.

Brief Summary: This phase 2, multicenter, randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of anisodine hydrobromide in patients with acute ischemic stroke undergoing endovascular thrombectomy.

Study Start Date: Aug. 31

Study Type: INTERVENTIONAL

Condition: Acute Ischemic Stroke

Intervention: DRUG: Anisodine Hydrobromide

Anisodine hydrobromide, 2 mg per dose, diluted in 0.9% sodium chloride solution and administered by intravenous infusion twice daily for a total of 14 do...